Delix Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 Authors Rd, Concord, Massachusetts, 0...Website
www.delixtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Delix Therapeutics
Founded in 2019, Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens-novel neuroplasticity-promoting therapeutics to better treat mental health disorders. Delix Therapeutics is located in MassachusettsExplore more
Delix Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Delix Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Delix Therapeutics is spiking on competitors!
Product Launch: Get notified when Delix Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Delix Therapeutics
Earning: See what the market has to say on Delix Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Delix Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Delix Therapeutics has new funding data
Delix Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Delix Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Delix Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Delix Therapeutics
Compare insights from companies similar to Delix Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Delix Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Delix Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Delix Therapeutics.
Delix Therapeutics financials insights
Gather financial insights about Delix Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$8M
2021
Series A
$70M
2022
Debt
$30M
Delix Therapeutics Tech Stack
A closer look at the technologies used by Delix Therapeutics
Most Recent Scoops
Event
Person-Based
David Olson, Head Chief Innovation Officer, The Scientific Advisory Board, appeared on a podcast called "The Readout Loud" on 12/04/2025. Topics discussed include Psychedelics, drug regulation, depression.
Events, Podcast
Left Company
Executive Move
Executive Moves, Left Company
Funding
Project
Award, Spending/Investment
Event
Events
Event
Events
Delix Therapeutics News & Media
Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress
BELFAST, Northern Ireland, Oct. 13, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data at the International Society for CNS Clinical...NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder
Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is effective at detecting a pharmacodynamic signal consistent with that previously observed in a healthy volunteer study BELFAST, Northern...Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Delix Therapeutics, a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced full results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2024 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Phoenix, Arizona. Preclinical data on DLX-159, a next-generation neuroplastogen, were aDelix Therapeutics Announces Dosing of First Patient in Phase 1b Clinical Trial for DLX-001 in Major Depressive Disorder
BEDFORD, Mass.--(BUSINESS WIRE)--Delix Therapeutics, a clinical-stage neuroscience company pioneering novel neuroplasticity-promoting treatments for psychiatric and neurological disorders, today announced that the first patient has been dosed in its Phase 1b clinical trial to evaluate the pharmacodynamics (PD), safety, tolerability, and pharmacokinetics (PK) of DLX-001, a novel non-hallucinogenic neuroplastogen, in Major Depressive Disorder (MDD). “Building on promising preclinical studies that
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Delix Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2019, Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens-novel neuroplasticity-promoting therapeutics to better treat mental health disorders. Delix Therapeutics is located in Massachusetts... Read More
